Deciphera Pharmaceuticals (DCPH) Misses Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Deciphera Pharmaceuticals (DCPH) Misses Q2 EPS by 6c

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results

August 3, 2021 4:01 PM EDT

- Second Quarter 2021 QINLOCK® Net Product Revenue of $22.0 Million -

- Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line Gastrointestinal Stromal Tumor (GIST) Expected in the Fourth Quarter of 2021 -

- First Patient Treated in Phase 1 Study of ULK Kinase Inhibitor DCC-3116 -

- Data from Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Rebastinib in Combination with Paclitaxel in Platinum-Resistant Ovarian Cancer to be Presented at the ESMO Congress 2021; Finalization of Pivotal Development Plans for both... More